Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Abstract Text:

A pure selenium deficiency is harmful to the heart and causes a fatal dilated congestive cardiomyopathy in animals (white muscle disease) and in man (Keshan disease). Both of these syndromes are selenium-responsive. A deficiency of the micronutrient has also been reported in patients with Friedreich's ataxia and there are histological similarities between Friedreich's cardiomyopathy and Keshan disease. A low selenium status results in reduced selenium-dependent glutathione peroxidase activity. This essential antioxidant enzyme protects membrances from oxidative deterioration, a function it shares in common with vitamin E. As iron-induced mitochondrial lipid peroxidation is central to the pathology of Friedreich's ataxia, the administration of selenium supplements should normalize the antioxidant activity of myocardial glutathione peroxidase and slow the progression of the life-shortening cardiomyopathy associated with this illness.

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Journal Published:

PUBLICATION TYPE: Journal Article

Journal: Medical hypotheses

VOLUME: 58

Page Numbers: 127-32

Journal Abbreviation: Med. Hypotheses

ISSN: 0306-9877

DAY: 15

MONTH: Feb

YEAR: 2002

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 7505668

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Keywords Mesh Terms:

KEYWORDS: White Muscle Disease

MESH TERMS: metabolism

Chemical & Substance for Abstract: Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia. Information

Substance Name: Glutathione Peroxidase

Registry Number: EC 1.11.1.9

Grant and Affiliation Information for Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.

AFFILIATION: John Tabor Laboratories, University of Essex, Colchester, UK. mfryer@essex.ac.uk

Country: Scotland

AGENCY:

GRANT:

ACRONYM:

MEDLINETA: Med Hypotheses

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia Related Publications

• Accumulation of heavy metals in unicellular algae.
• Antigen sensitization influences organophosphorus pesticide-induced airway hyperreactivity.
• Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism.
• Chromatin modulation of glucocorticoid and progesterone receptor activity.
• Comparative effects of levosimendan, OR-1896, OR-1855, dobutamine, and milrinone on vascular resistance, indexes of cardiac function, and O2 consumption in dogs.
• Comparing the strength of behavioural plasticity and consistency across situations: animal personalities in the hermit crab Pagurus bernhardus.
• Comprehending Care in a Medical Home: A Usual Source of Care and Patient Perceptions about Healthcare Communication.
• Correction of bronchial challenge data for age and size may affect the results of genetic association studies in children.
• Dementing disease in a married couple.
• Direct elemental analysis of biodiesel by inductively coupled plasma-mass spectrometry.
• Evoked changes in cardiovascular function in rats by infusion of levosimendan, OR-1896 [(R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)acetamide], OR-1855 [(R)-6-(4-aminophenyl)-5-methyl-4,5-dihydropyridazin-3(2H)-one], dobutamine, and m
• Exercise class participation among residents in low-level residential aged care could be enhanced: a qualitative study.
• Exposure to cigarette advertising and adolescents' intentions to smoke: the moderating role of the developing self-concept.
• Expression and regulation of intercellular adhesion molecule-1 on airway parasympathetic nerves.
• Facial paralysis supported with autogenous fascia lata.
• Fallacy of term self-healing epidermoid carcinoma and limitations of microscopic interpretations.
• Hypomagnesemia and hypokalemia in 1,000 treated ambulatory hypertensive patients.
• Impact of parenteral nutrition-associated liver disease on intestinal transplant waitlist dynamics.
• Intravenous magnesium--potential hazard of inadequate mixing.
• Patients with truncal basal cell carcinoma represent a high-risk group.
• Perceptions of healthcare providers' communication skills: Do they differ between urban and non-urban residents?
• Plastic surgery for severe facial paralysis in elderly patients.
• Practical barriers to timely primary care access: impact on adult use of emergency department services.
• Radiation burns, including vocational and atomic exposures; treatment, and surgical prevention of chronic lesions.
• Rationale for clinical trials of selenium as an antioxidant for the treatment of the cardiomyopathy of Friedreich's ataxia.
• Surgical treatment of radiation burns.
• The current status of intestinal transplantation.
• The possible role of nitric oxide and impaired mitochondrial function in ataxia due to severe vitamin E deficiency.
• The role of nutrition in oral leukoplakia including a therapeutic trial of topical vitamin A.
• Treatment of acute renal failure with antioxidant vitamin E.